BIO Asia–Taiwan 2025 Highlight｜Asia’s Premium Biotech Event

Описание: A comprehensive 3-minute recap of Asia’s flagship biotech convergence, bringing together over 140,000 visitors, 850+ exhibitors, 12 national pavilions, 3,000+ conference participants, and 8,800+ partnering requests.
A snapshot of the scientific, industrial, and investment forces shaping the region.

BIO Asia–Taiwan is one of the three globally authorized BIO events, jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO).
The 2025 edition, themed “Next Wave of Biotech Opportunities,” showcased Asia’s rapid advancement across R&D, clinical development, manufacturing, investment, and cross-border collaboration.

⸻

International Participation (Conference + Exhibition + Partnering)

Conference: 3,000+ participants from 30+ countries
Exhibition: 850+ exhibitors, 2,200+ booths, over 140,000 visitors
Overall event: Participants from 58 countries
BIO Partnering™: 8,800+ meeting invitations (+15% YoY)

⸻

National Pavilions — 12 Official Pavilions

United States, Switzerland, Japan, Australia, Poland, Belgium, Austria, Malaysia, Thailand, India, Hong Kong, Philippines.

⸻

Program Highlights

The conference explored major drivers shaping Asia’s biotech momentum, including policy development, pharmaceutical innovation, clinical and manufacturing advances, AI and data governance, precision health, biomedical big data, digital health, smart healthcare, and investment strategies.
Topics ranged from new therapeutic modalities, gene and cell therapy manufacturing, ADC and antibody engineering, CMC and biologics development, AI-enabled drug discovery, translational medicine, digital health applications, to cross-border collaboration—representing the full biotech value chain.

Explore the full 2025 conference program:
https://bioasiataiwan.com/en/program/...

⸻

Key Participating Companies

AbbVie, Acer Medical, Amgen, AP Biosciences, BD, Bora Pharmaceuticals, Charles River, Chugai, CMIC, Cytiva, DCI Partners, Dr. Reddy’s, Daiichi Sankyo, EirGenix, Fareastone, Formosa Laboratories, Foxconn, Fujifilm, GE HealthCare, Google Cloud, GSK, HiRO, ICON, Illumina, Labcorp, Lonza, Medidata, Merck, Novartis, Novo Nordisk, Novotech, OBI Pharma, Revvity, Syneos Health, TaiMed Biologics, TBMC, Thermo Fisher Scientific, Foresee Pharmaceuticals, PharmaEssentia.

⸻

Post-Event Report Download

Full 2025 Post-Event Report (PDF):
https://drive.google.com/file/d/1rYxB...

⸻

BIO Asia–Taiwan continues to serve as Asia’s leading platform connecting science, industry, healthcare, and investment to drive global biotech innovation.

⸻

Event Dates

2025: Held on July 23–27
2026: July 15–19 (TaiNEX 1 & 2)
Organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO)

Thank you for being part of this year’s event.
See you in Taipei in July 2026.

⸻

BIO Asia–Taiwan 亞洲生技大會為全球三大 BIO 官方授權展會之一，由 全球生物技術創新組織（BIO）與台灣生物產業發展協會（Taiwan BIO） 共同主辦。本屆以「掌握亞洲生技新契機」為主題，呈現亞洲在研發、臨床、製造、投資與跨境合作上的全面提升。

行政院長蒞臨開幕典禮指出，台灣生技產業 2024 年營業額已突破新台幣 7,754 億元，創下歷史新高，顯示生技已成為下一階段經濟成長的關鍵動能。行政院長並指出，政府將持續推動精準健康、再生醫療、AI 醫療與臨床試驗國際接軌等政策方向，支持台灣生技產業加速邁向全球市場。
官方新聞稿：
https://www.ey.gov.tw/Page/AF73D47199...

⸻

【國際參與（Conference + Exhibition + Partnering）】

論壇：3,000+ 參與者，來自 30+ 國
展覽：850+ 參展商、2,200+ 展位、14 萬+ 參觀人次
全體活動：參與者來自 58 國
BIO Partnering™：8,800+ 商機媒合邀請（年增 15%）

⸻

【生技大展參展國家館 — 12 個官方國家館】

美國、瑞士、日本、澳洲、波蘭、比利時、奧地利、馬來西亞、泰國、印度、香港、菲律賓。

⸻

【論壇議題亮點】

本屆論壇聚焦亞洲生技核心技術與產業動能，包括跨國政策、醫藥研發創新、臨床與製程升級、AI 與資料治理、精準健康、生醫大數據、智慧醫療、生技投資與跨境協作等。
議題涵蓋新療法、基因與細胞治療製造、ADC 與抗體工程、CMC 與生物製劑開發、AI 新藥研發、轉譯醫學、數位健康、生醫科技應用與投資策略，呈現生技從科學到商業化的完整鏈結。

完整 2025 年議程（英文）：
https://bioasiataiwan.com/en/program/...

⸻

【指標參與企業（展覽 + 論壇 + 投資 + 媒合 + 贊助）】

AbbVie、Acer Medical、Amgen、AP Biosciences、BD、Bora Pharmaceuticals、Charles River、Chugai、CMIC、Cytiva、DCI Partners、Dr. Reddy’s、Daiichi Sankyo、EirGenix、Fareastone、Formosa Laboratories、Foxconn、Fujifilm、GE HealthCare、Google Cloud、GSK、HiRO、ICON、Illumina、Labcorp、Lonza、Medidata、Merck、Novartis、Novo Nordisk、Novotech、OBI Pharma、Revvity、Syneos Health、TaiMed Biologics、TBMC、Thermo Fisher Scientific、Foresee Pharmaceuticals、PharmaEssentia。

⸻

【展後報告下載】

完整 2025 年展後報告（PDF）：
https://drive.google.com/file/d/1rYxB...

⸻

BIO Asia–Taiwan 持續以亞洲最具代表性的國際生技平台，連結科研、產業、醫療與投資生態系，推動全球生技創新的下一階段成長。

⸻

【活動日期】

2025：已於 7 月 23–27 日舉辦
2026：7 月 15–19 日（台北南港展覽館 1 & 2）
主辦單位：全球生物技術創新組織（BIO）、台灣生物產業發展協會（Taiwan BIO）

感謝今年所有參與者的支持，
2026 年七月，台北再見。

#BIOAsiaTaiwan #AsiasPremiumBiotechEvent
#Biotech #Biopharma #LifeSciences
#BiotechConference #BiotechExhibition
#AIDrugDiscovery #PrecisionHealth #RegenerativeMedicine
#ClinicalTrials #DigitalHealth #SmartHealthcare
#BiotechInvestment #GlobalBiotech #AsiaBiotechHub
#BiotechPartnering #innovationecosystem